Epithalon vs MOTS-c: telomerase and circadian signalling against mitochondrial AMPK activation — mechanisms, half-life, and what the published research actually supports for each.
Epithalon and MOTS-c are both filed under "longevity peptides," and that shared label hides almost everything worth knowing about them. One is a synthetic four-amino-acid sequence designed in a Soviet-era gerontology institute to act on the pineal-neuroendocrine axis. The other is a sixteen-amino-acid peptide encoded inside the mitochondrial genome, discovered in 2015, that behaves like a molecular signal of exercise. They share a research audience, not a mechanism, and their evidence bases fail in different places.
| Epithalon (AEDG) | MOTS-c | |
|---|---|---|
| Structure | Synthetic tetrapeptide, Ala-Glu-Asp-Gly | Endogenous 16-amino-acid peptide encoded in the mitochondrial 12S rRNA gene |
| Origin | Vladimir Khavinson, St. Petersburg Institute of Bioregulation and Gerontology, 1980s; modelled on the pineal extract epithalamin | Changhan Lee and Pinchas Cohen, USC; Cell Metabolism, 2015 |
| Proposed mechanism | hTERT expression and telomerase activation; restoration of nocturnal melatonin rhythm | AMPK activation, nuclear translocation under metabolic stress, folate–methionine cycle modulation |
| Strongest evidence | Telomerase induction in human cell culture (PMID 12937682), independently replicated in 2025 (PMID 40908429) | Rodent metabolic and physical-capacity data, including late-life dosing in aged mice (PMID 33384494) |
| Rodent lifespan data | Anisimov 2003 (PMID 14501183): mean lifespan unchanged; last-decile lifespan +13.3%, maximum +12.3% | No lifespan trial; healthspan and physical-function endpoints only |
| Human interventional data | Two small unblinded studies from the originating institute, neither by the subcutaneous route | None completed for MOTS-c itself; nearest is CB4211, an analog, in a company-reported Phase 1a/1b |
| Published half-life | None. No primary human PK study exists | Not formally characterised; reported on the order of hours in animal work |
| Research route | Subcutaneous | Subcutaneous |
| Framing in protocols | Geroprotection, circadian restoration | Exercise mimetic, metabolic regulation |
Epithalon's central claim is telomerase. Khavinson's group reported in 2003 that adding the tetrapeptide to telomerase-negative human fetal fibroblasts induced the catalytic subunit, raised enzyme activity, and elongated telomeres. Unusually for this literature, an unaffiliated group at Brunel University London reproduced dose-dependent telomere lengthening in normal human cells in 2025 — while also observing that two breast cancer lines lengthened telomeres through the ALT pathway instead, a reminder that telomere maintenance is not intrinsically pro-longevity. A secondary strand concerns melatonin: aged rodents show a blunted nocturnal peak, and the peptide is reported to restore a more youthful diurnal pattern.
MOTS-c works on a completely different node. It activates AMPK, the cell's energy sensor — the same switch pulled by caloric restriction, metformin, and exercise itself. Under metabolic stress it translocates to the nucleus and engages stress-adaptive gene programs. Endogenous MOTS-c rises with exercise and declines with age, which gives it something Epithalon does not have: a measurable circulating baseline that ties the aging hypothesis to an actual biomarker.
So the comparison is not "which is the stronger longevity peptide." It is telomere biology and circadian signalling versus mitochondrial energy sensing and substrate metabolism. Nothing about the first predicts the second.
Both compounds are early-stage, but they are early-stage in different ways.
Epithalon's problem is concentration and blinding. Most of the literature comes from one institute, and no blinded human trial exists. The frequently-quoted human mortality result — 266 older adults, mortality reduced 1.6–1.8-fold — belongs to Khavinson & Morozov 2003 (PMID 14523363) and studied Thymalin and Epithalamin, the tissue extracts, not the synthetic tetrapeptide. The rodent lifespan finding is real but narrower than its reputation: mean lifespan did not move. A 2025 review in the International Journal of Molecular Sciences (PMID 40141333) notes that even the physico-chemical characterisation of the molecule remains limited.
MOTS-c's problem is species. The preclinical work is stronger and more independent than Epithalon's — Reynolds et al. 2021 in Nature Communications reported that intermittent treatment begun late in life improved running capacity, grip strength, and gait in aged mice — but there is no completed randomized trial of MOTS-c itself with published human outcomes. The closest human data is CohBar's CB4211, an engineered MOTS-c analog, whose 2021 Phase 1a/1b topline reported acceptable tolerability and reductions in ALT and AST with a downward trend in body weight. That was a company press release, not a peer-reviewed paper, and the molecule was an analog, not MOTS-c. Human MOTS-c work is otherwise observational: exercise-response measurements and genetic association studies, notably the Asian-specific K14Q variant (m.1382A>C) linked in Japanese cohorts to exceptional longevity and, in later work, to muscle fibre composition and performance.
One practical caution when checking either compound yourself: trial registries are not curated. A batch of fictional peptide study records has been documented on ClinicalTrials.gov, at least one of which openly describes itself as an example record while displaying as recruiting. Read the sponsor and the results section, not the status badge. Our guide on how to read a peptide study covers the rest of that checklist.
If the question is telomere dynamics, cellular senescence markers, or circadian and melatonin endpoints, Epithalon is the compound with the mechanistic literature behind it — and the one whose in-vitro finding survived independent replication. Everything above that cell-culture layer is thin.
If the question is metabolic — insulin sensitivity, substrate utilisation, mitochondrial function, exercise capacity, age-related physical decline — MOTS-c is the better-matched tool. Its preclinical base is more recent, more independent, and measured against endpoints that translate more cleanly than a telomere-length assay.
The two are commonly stacked precisely because the mechanisms are orthogonal; the sleep and longevity peptides overview covers that grouping alongside DSIP. The logic is coherent, and evidence that the combination outperforms either alone does not exist. For depth on each compound individually, see the Epithalon research overview and the MOTS-c research overview.
Is Epithalon or MOTS-c better for longevity research? Neither is "better" in a general sense — they address different mechanisms. Epithalon is the telomerase and circadian candidate; MOTS-c is the mitochondrial and metabolic candidate. MOTS-c currently has the more recent and more independently produced preclinical dataset; Epithalon has the longer track record and one independently replicated in-vitro finding. Both lack blinded human outcome trials.
Can Epithalon and MOTS-c be studied together? They are frequently combined in longevity-oriented protocols because their mechanisms do not overlap. No published study has tested the combination against either compound alone, so any synergy claim is a hypothesis rather than a finding.
Does either one have a published half-life? No primary human pharmacokinetic study of Epithalon has been published, so the "minutes" figure circulating online is not sourced to measured data. MOTS-c half-life has been reported on the order of hours in animal work, but human steady-state kinetics are not fully characterised. Reconstitution and concentration math is covered in our dosing math guide.
Has MOTS-c been tested in humans? Not as a completed interventional trial of the peptide itself with published outcomes. Human work to date is observational — exercise-response and genetic association studies. The nearest interventional data comes from CB4211, a MOTS-c analog, in a company-reported Phase 1a/1b study.
Why is so much Epithalon research Russian? The molecule was synthesized at the St. Petersburg Institute of Bioregulation and Gerontology and remains that group's research focus, so the evidence base is concentrated in one laboratory. Independent work exists but is sparse — a 2025 UK replication of the telomerase result and a 2025 Polish review are the notable exceptions.
